The study found that UFH reduced the relative 28-day mortality rate by 16%, with no significant bleeding complications. Nearly all patients with sepsis experienced abnormalities in coagulation, ranging from minor changes to disseminated intravascular coagulation. Anticoagulants such as thrombomodulin and a tissue factor pathway inhibitor have been examined to ameliorate sepsis mortality and have proven ineffective thus far. However, in this study, researchers found that UFH plays more than a simple anticoagulant role and has numerous protective effects, such as enhancing endothelial barrier function and mediating nuclear factor kappa B activation.
Learn more about heparin.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Richard H. Sinert. Rapid Review: Sepsis - Medscape - Apr 08, 2022.